Polaris 24 adjustable valve for people with hydrocephalus
Looks at how safe and well the Polaris 24 valve works in 126 patients.
Key facts
- Who runs it
- Sophysa
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment
- Status
- Recruiting
- People taking part
- 126 people, planned
- Started
- 4 Jun 2021
- Expected to end
- Jun 2033
- Type of study
- Observational
- Record updated
- 27 January 2026
Who can take part
The trial is looking for people with hydrocephalus (fluid build-up in the brain) who have had the Polaris® 24 adjustable valve system implanted.
- Sex
- All sexes can join.
- Disease stage
- Hydrocephalus treated with the Polaris® 24 valve as a first shunt implant, as a replacement of another valve-based shunt, or after endoscopic ventriculostomy (EVT) failed.
- Earlier treatment
- People must have been implanted with the Polaris® 24 adjustable valve system.
- Main reasons for not taking part
- Confirmed or suspected infection along the shunt, or any infection anywhere in the body
- Taking blood-thinning (anticoagulant) medicine
- A bleeding disorder, or blood in the brain fluid (CSF)
- A shunt draining into the heart (ventriculo-atrial) in people with heart defects from birth or other heart-lung malformations
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Patient implanted with the Polaris® 24 adjustable valve system for the following reasons:; Primo implant of a valve shunt-based derivation system, or as a; Replacement of another valve -based shunt system, or; Endoscopic ventriculostomy (EVT) failure
- Patient having given his/her informed consent prior to inclusion in this study, as per local regulations
Who cannot take part
- Confirmed or suspected infections along the length of the shunt (meningitis, ventriculitis, peritonitis, septicemia or bacteremia) or any infection present in any part of the body
- Patient on anticoagulant therapy, or presenting with bleeding diathesis, or with haemorrhagic CSF, as the presence of blood in the system could lead to an obstruction in the system
- Ventriculo-atrial shunts in patient suffering from congenital cardiopathies or other malformations of the cardio-pulmonary system
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Hydrocephalus
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The SAPPHYRE study is an ambispective (retrospective and prospective) PMCF study with the objective to evaluate the safety and performance of the Polaris® 24 adjustable valve system in the treatment of 126 patients with hydrocephalus.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment
- Plain-language title
- Polaris 24 adjustable valve for people with hydrocephalusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT04746625, who can take part
- Record updated
- 27 January 2026